Article Type
Changed
Fri, 06/28/2024 - 11:05

 

TOPLINE:

In men with type 2 diabetes (T2D), higher serum levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were associated with a lower risk for metabolic dysfunction–associated fatty liver disease (MAFLD), whereas higher progesterone levels were associated with a higher risk. In women with T2D, sex- or thyroid-related hormones were not independently associated with the risk for MAFLD.

METHODOLOGY:

  • People with T2D may have FLD, and this study explored the link between sex-related and thyroid-related hormone levels and MAFLD to explore and confirm risk factors.
  • The researchers used a 2020 definition of MAFLD, now defined in patients as both hepatic steatosis and the presence of overweight/obesity, T2D, or evidence of metabolic dysfunction in lean individuals.
  • This cross-sectional study conducted in one hospital in China included 432 patients hospitalized because of T2D and its complications from January 2018 to April 2020 (median T2D duration, 6 years; mean age, 55.8 years; 247 men and 185 postmenopausal women).
  • Researchers measured and later adjusted for potential confounding factors, including weight, height, waist circumference, arterial blood pressure, glycemic parameters, liver function, and lipid profiles.
  • They assessed blood levels of sex and thyroid hormones by chemiluminescent immunoassays; MAFLD was diagnosed by either ultrasonography findings of hepatic steatosis or a high liver fat index score (fatty liver index > 60).

TAKEAWAY:

  • Overall, 275 (63.7%) patients were diagnosed with MAFLD; after adjusting for potential confounding factors, none of the sex- and thyroid-related hormones were independently associated with the risk for MAFLD in all patients with T2D.
  • In men with T2D, higher serum levels of FSH (adjusted odds ratio [aOR], 0.919; P = .019) and LH (aOR, 0.888; P = .022) were associated with a reduced risk for MAFLD.
  • Higher serum levels of progesterone were associated with an increased risk for MAFLD in men with T2D (aOR, 8.069; P = .003).
  • In women with T2D, sex hormones and thyroid hormones were not significantly linked to the risk of developing MAFLD.

IN PRACTICE:

“Our findings could be used to imply that screening for MAFLD and monitoring sex-related hormones are important for T2D patients, especially in men,” the authors wrote.

SOURCE:

This study was led by Weihong Lu, Xiamen Clinical Research Center for Cancer Therapy, Xiamen, China; Shangjian Li, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China; and Yuhua Li, China University of Mining & Technology-Beijing, Beijing, and was published online in BMC Endocrine Disorders.

LIMITATIONS:

Temporal sequences of the associations between sex-related and thyroid-related hormones and MAFLD were not evaluated because of the cross-sectional nature of the study. The small sample size from a single institution may have introduced selection bias. Serum levels of sex hormone-binding globulin and free testosterone were not assessed. The postmenopausal status of women in the study may have affected the ability to find sex-hormone related associations. The findings can only be limitedly extrapolated to similar patients with T2D but not the general population.

DISCLOSURES:

The study was supported by the Fujian Province Nature Science Foundations, China, and the Guiding Project on Medicine and Health in Xiamen, China. The authors declared no conflicts of interest.

A version of this article first appeared on Medscape.com.

Publications
Topics
Sections

 

TOPLINE:

In men with type 2 diabetes (T2D), higher serum levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were associated with a lower risk for metabolic dysfunction–associated fatty liver disease (MAFLD), whereas higher progesterone levels were associated with a higher risk. In women with T2D, sex- or thyroid-related hormones were not independently associated with the risk for MAFLD.

METHODOLOGY:

  • People with T2D may have FLD, and this study explored the link between sex-related and thyroid-related hormone levels and MAFLD to explore and confirm risk factors.
  • The researchers used a 2020 definition of MAFLD, now defined in patients as both hepatic steatosis and the presence of overweight/obesity, T2D, or evidence of metabolic dysfunction in lean individuals.
  • This cross-sectional study conducted in one hospital in China included 432 patients hospitalized because of T2D and its complications from January 2018 to April 2020 (median T2D duration, 6 years; mean age, 55.8 years; 247 men and 185 postmenopausal women).
  • Researchers measured and later adjusted for potential confounding factors, including weight, height, waist circumference, arterial blood pressure, glycemic parameters, liver function, and lipid profiles.
  • They assessed blood levels of sex and thyroid hormones by chemiluminescent immunoassays; MAFLD was diagnosed by either ultrasonography findings of hepatic steatosis or a high liver fat index score (fatty liver index > 60).

TAKEAWAY:

  • Overall, 275 (63.7%) patients were diagnosed with MAFLD; after adjusting for potential confounding factors, none of the sex- and thyroid-related hormones were independently associated with the risk for MAFLD in all patients with T2D.
  • In men with T2D, higher serum levels of FSH (adjusted odds ratio [aOR], 0.919; P = .019) and LH (aOR, 0.888; P = .022) were associated with a reduced risk for MAFLD.
  • Higher serum levels of progesterone were associated with an increased risk for MAFLD in men with T2D (aOR, 8.069; P = .003).
  • In women with T2D, sex hormones and thyroid hormones were not significantly linked to the risk of developing MAFLD.

IN PRACTICE:

“Our findings could be used to imply that screening for MAFLD and monitoring sex-related hormones are important for T2D patients, especially in men,” the authors wrote.

SOURCE:

This study was led by Weihong Lu, Xiamen Clinical Research Center for Cancer Therapy, Xiamen, China; Shangjian Li, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China; and Yuhua Li, China University of Mining & Technology-Beijing, Beijing, and was published online in BMC Endocrine Disorders.

LIMITATIONS:

Temporal sequences of the associations between sex-related and thyroid-related hormones and MAFLD were not evaluated because of the cross-sectional nature of the study. The small sample size from a single institution may have introduced selection bias. Serum levels of sex hormone-binding globulin and free testosterone were not assessed. The postmenopausal status of women in the study may have affected the ability to find sex-hormone related associations. The findings can only be limitedly extrapolated to similar patients with T2D but not the general population.

DISCLOSURES:

The study was supported by the Fujian Province Nature Science Foundations, China, and the Guiding Project on Medicine and Health in Xiamen, China. The authors declared no conflicts of interest.

A version of this article first appeared on Medscape.com.

 

TOPLINE:

In men with type 2 diabetes (T2D), higher serum levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were associated with a lower risk for metabolic dysfunction–associated fatty liver disease (MAFLD), whereas higher progesterone levels were associated with a higher risk. In women with T2D, sex- or thyroid-related hormones were not independently associated with the risk for MAFLD.

METHODOLOGY:

  • People with T2D may have FLD, and this study explored the link between sex-related and thyroid-related hormone levels and MAFLD to explore and confirm risk factors.
  • The researchers used a 2020 definition of MAFLD, now defined in patients as both hepatic steatosis and the presence of overweight/obesity, T2D, or evidence of metabolic dysfunction in lean individuals.
  • This cross-sectional study conducted in one hospital in China included 432 patients hospitalized because of T2D and its complications from January 2018 to April 2020 (median T2D duration, 6 years; mean age, 55.8 years; 247 men and 185 postmenopausal women).
  • Researchers measured and later adjusted for potential confounding factors, including weight, height, waist circumference, arterial blood pressure, glycemic parameters, liver function, and lipid profiles.
  • They assessed blood levels of sex and thyroid hormones by chemiluminescent immunoassays; MAFLD was diagnosed by either ultrasonography findings of hepatic steatosis or a high liver fat index score (fatty liver index > 60).

TAKEAWAY:

  • Overall, 275 (63.7%) patients were diagnosed with MAFLD; after adjusting for potential confounding factors, none of the sex- and thyroid-related hormones were independently associated with the risk for MAFLD in all patients with T2D.
  • In men with T2D, higher serum levels of FSH (adjusted odds ratio [aOR], 0.919; P = .019) and LH (aOR, 0.888; P = .022) were associated with a reduced risk for MAFLD.
  • Higher serum levels of progesterone were associated with an increased risk for MAFLD in men with T2D (aOR, 8.069; P = .003).
  • In women with T2D, sex hormones and thyroid hormones were not significantly linked to the risk of developing MAFLD.

IN PRACTICE:

“Our findings could be used to imply that screening for MAFLD and monitoring sex-related hormones are important for T2D patients, especially in men,” the authors wrote.

SOURCE:

This study was led by Weihong Lu, Xiamen Clinical Research Center for Cancer Therapy, Xiamen, China; Shangjian Li, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China; and Yuhua Li, China University of Mining & Technology-Beijing, Beijing, and was published online in BMC Endocrine Disorders.

LIMITATIONS:

Temporal sequences of the associations between sex-related and thyroid-related hormones and MAFLD were not evaluated because of the cross-sectional nature of the study. The small sample size from a single institution may have introduced selection bias. Serum levels of sex hormone-binding globulin and free testosterone were not assessed. The postmenopausal status of women in the study may have affected the ability to find sex-hormone related associations. The findings can only be limitedly extrapolated to similar patients with T2D but not the general population.

DISCLOSURES:

The study was supported by the Fujian Province Nature Science Foundations, China, and the Guiding Project on Medicine and Health in Xiamen, China. The authors declared no conflicts of interest.

A version of this article first appeared on Medscape.com.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article